welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
active, not recruiting
Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
study id #: NCT02667483
condition: Duchenne Muscular Dystrophy
status: active, not recruiting
purpose:This is a phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetic (PK) profile of DS-5141b in patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping and to determine the dosage for subsequent studies.
intervention: DS-5141b
mechanism of action: Exon-skipping to promote dystrophin production
results: https://clinicaltrials.gov/ct2/show/results/NCT02667483
last updated: June 24, 2020
study details
study contacts
rareRelated
-
Systemic Gene Delivery Clinical Trial for Duchenne Muscular DystrophyThe proposed clinical trial is a single-...
-
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
-
Treatment Effect of Tamoxifen on Patients With DMDDuchenne muscular dystrophy (DMD) is a p...
-
PDE Inhibitors in DMD Study (Acute Dosing Study)PDE5A inhibition, which boosts NO-cGMP s...
-
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular DystrophyThis is a first-in-human/first-in-patien...
-
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
-
An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability DeflazacortThis is an open label, long-term extensi...
-
DuchenneXchange Clinical Trial Finder LaunchesThe DuchenneXchange Clinical Trial Finde...
-
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy ProgramSarepta Therapeutics, Inc., the leader i...
-
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
-
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...
-
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
